Clinical stage T1c prostate cancer: Evaluation with endorectal MR imaging and MR spectroscopic imaging

Radiology

Volumn 253, Issue 2, 2009, Pages 425-434

  Zhang, Jingbo ^a   Hricak, Hedvig ^a   Shukla Dave, Amita ^a   Akin, Oguz ^a   Ishill, Nicole M ^a   Carlino, Lauren J ^a   Reuter, Victor E ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER NECK; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOLOGIST; RECEIVER OPERATING CHARACTERISTIC; SEMINAL VESICLE; TUMOR VOLUME;

ADULT; AGED; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 77950140292     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2532081390     Document Type: Article

References (40)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta, Ga: American Cancer Society, 2009.
2. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
3. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-138.
4. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155:816-820.
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368 -374.
6. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997;157:2206-2209.
7. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
8. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993;43:7-26.
9. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
10. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
11. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-1301.
12. Bernstein MR, Cangiano T, D'Amico A, et al. Endorectal coil magnetic resonance imaging and clinicopathologic findings in T1c adenocarcinoma of the prostate. Urol Oncol 2000;5:104-107.
13. Bottomley P. Selective volume method for performing localized NMR spectroscopy. U.S. patent 4,480,228, October 30, 1984.
14. 3) spatial resolution. Radiology 1996;198:795-805.
15. Males RG, Vigneron DB, Star-Lack J, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43:17-22.
16. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 2001;46:1079-1087.
17. Tran TK, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000;43:23-33.
18. Pels P, Ozturk-Isik E, Swanson MG, et al. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed 2006;19:188-197.
19. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814.
20. Zakian KL, Eberhardt S, Hricak H, et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging - initial results. Radiology 2003;229:241-247.
21. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007;99:786-793.
22. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997;157:559-562.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating curves: a nonparametric approach. Biometrics 1988;44:837-845.
24. Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009;181:1635-1641.
25. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Outcomes Research Team. JAMA 1993;269:2650-2658.
26. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994;152:1894-1899.
27. Yoshimura N, Takami N, Ogawa O, et al. Decision analysis for treatment of early stage prostate cancer. Jpn J Cancer Res 1998;89:681-689.
28. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-2411.
29. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 1997;157:244-250.
30. Douglas TH, McLeod DG, Mostofi FK, et al. Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. Prostate 1997;32:59-64.
31. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-1063.
32. Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol 1996;155:821-826.
33. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999;213:473-480.
34. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-404.
35. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-488.
36. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology 2007;245:176-185.
37. Fütterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-458.
38. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008;18:71-77.
39. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 2008;246:480-488.
40. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239:784-792.